display

Germany is also suspending corona vaccinations with the preparation from the manufacturer Astrazeneca as a precaution.

The Federal Ministry of Health announced on Monday and referred to a current recommendation from the Paul Ehrlich Institute.

Accordingly, after new reports of thrombosis of the cerebral veins in connection with the vaccination in Germany and Europe, the institute considers further investigations necessary.

The European Medicines Agency (EMA) will decide "whether and how the new findings will affect the approval of the vaccine".

Several countries have now suspended vaccination with the preparation after reports of side effects.

On Thursday Denmark first stopped vaccination with the vaccine and referred to several cases of severe blood clots after vaccination with Astrazeneca.

This was followed by Norway, Iceland and the EU countries Bulgaria, Ireland and, on Sunday evening, the Netherlands.

Austria, Estonia, Latvia, Lithuania and Luxembourg suspended the use of a certain Astrazeneca batch, Italy and Romania stopped the use of another batch.

Manufacturer does not see an increased risk of blood clots

display

The European Medicines Agency (EMA) has not yet seen any indications that the cases of blood clots were caused by the vaccination with AstraZeneca.

The EMA stressed last week that the information available so far showed that the number of thromboembolic incidents in vaccinated people is no higher than in the general population.

As of March 10, 30 cases of thromboembolic incidents had been reported among the nearly five million people vaccinated so far in the EU with the AstraZeneca agent.

AstraZeneca defended its vaccine after the vaccine bans whirlwind.

The pharmaceutical company does not see an increased risk of blood clots in connection with the vaccine.

A careful analysis of all available safety data from more than 17 million people vaccinated with the product in the European Union and the UK showed no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or a decrease in blood platelets.

So far, 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism have been reported, which is comparable to other approved Covid-19 vaccines.